Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit—TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit

Andrew Bivard(Hunter Medical Research Institute), Mark Parsons(UNSW Sydney), Geoffrey Cloud(Monash University), Angelos Sharobeam(The University of Melbourne), Leonid Churilov(The University of Melbourne), Nawaf Yassi, Bernard Yan(Centre hospitalier universitaire d'Orléans), Henry Zhao(Monash University), Tissa Wijeratne(Sunshine Hospital), Francesca Langenberg(The Royal Melbourne Hospital), Angela Dos Santos(Ambulance Victoria), Geoffrey A. Donnan(The Royal Melbourne Hospital), Michael Valente(The University of Melbourne), Vincent Thijs(Florey Institute of Neuroscience and Mental Health), Steve Bernard(Ambulance Victoria), Karen Smith(University of North Carolina at Chapel Hill), Philip Choi, Skye Coote(The Royal Melbourne Hospital), Henry Ma(Monash University), Anna Balabanski(Ambulance Victoria), Felix Ng(Capital Medical University), Michael Stephenson(Ambulance Victoria), Liudmyla Olenko(The University of Melbourne), Bruce Campbell(The Royal Melbourne Hospital), Stephen M. Davis(The Royal Melbourne Hospital), Chushuang Chen(Liverpool Hospital)
BMJ Open
April 1, 2022
Cited by 8


Related Papers